<DOC>
	<DOC>NCT00971867</DOC>
	<brief_summary>The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects</brief_summary>
	<brief_title>Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139388) and should have continued therapy with aclitaxel as the discretion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>